Cor Vasa 2021, 63(5):579-582 | DOI: 10.33678/cor.2021.045

The caveolin levels in cardiovascular disease

Lutfu Askina, Husna Sengul Askinb, Okan Tanriverdia
a Department of Cardiology, Adiyaman Education and Research Hospital, Adiyaman, Turkey
b Department of Infectious Diseases, Adiyaman Education and Research Hospital, Adiyaman, Turkey

Cardiovascular diseases (CVDs) are common diseases that cause many deaths around the world. Caveolin is a structural caveolae protein with three isoforms (Caveolin-1 [Cav-1], Cav-2, and Cav-3). Caveolae has a vital role in generating survival signals for cardiac protection. In particular, Cav-1 influences many biological processes (cellular energy balance, cellular destruction, and fibrosis) in the development of heart failure (HF). Decreased caveolin levels are a therapeutic target and could shed light on future studies in elderly and obese patients. In this review, we discussed the significance of caveolae in cardiovascular diseases. We have also emphasized the role of caveolin in many cardiovascular diseases.

Keywords: Cardiovascular diseases, Caveolin, Heart failure

Received: March 2, 2021; Revised: March 2, 2021; Accepted: April 3, 2021; Published: October 20, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Askin L, Askin HS, Tanriverdi O. The caveolin levels in cardiovascular disease. Cor Vasa. 2021;63(5):579-582. doi: 10.33678/cor.2021.045.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics - 2010 update: A report from the American Heart Association. Circulation 2010;121:E46-E215.
    2. Askin L, Tanriverdi O, Tibilli H, et al. Associations between Vaspin Levels and Coronary Artery Disease. Cardiovasc Innov Appl 2020;4:211-216. Go to original source...
    3. Mio Y, Bienengraeber MW, Marinovic J, et al. Age-related attenuation of isoflurane preconditioning in human atrial cardiomyocytes: Roles for mitochondrial respiration and sarcolemmal adenosine triphosphate-sensitive potassium channel activity. Anesthesiology 2008;108:612-620. Go to original source... Go to PubMed...
    4. Boengler K, Konietzka I, Buechert A, et al. Loss of ischemic preconditioning's cardioprotection in aged mouse hearts is associated with reduced gap junctional and mitochondrial levels of connexin 43. Am J Physiol Heart Circ Physiol 2007;292:H1764-H1769. Go to original source... Go to PubMed...
    5. Boengler K, Schulz R, Heusch G. Loss of cardioprotection with ageing. Cardiovasc Res 2009;83:247-261. Go to original source... Go to PubMed...
    6. Williams TM, Lisanti MP. The caveolin proteins. Genome Biol 2004;5:214. Go to original source... Go to PubMed...
    7. Vinten J, Johnsen AH, Roepstorff P, et al. Identification of a major protein on the cytosolic face of caveolae. Biochim Biophys Acta 2005;1717:34-40. Go to original source... Go to PubMed...
    8. Liu L, Pilch PF. A critical role of cavin (polymerase i and transcript release factor) in caveolae formation and organization. J Biol Chem 2008;283:4314-4322. Go to original source... Go to PubMed...
    9. Insel PA, Patel HH. Membrane rafts and caveolae in cardiovascular signaling. Curr Opin Nephrol Hypertens 2009;18:50-56. Go to original source... Go to PubMed...
    10. Simons K, Ehehalt R. Cholesterol, lipid rafts, and disease. J Clin Invest 2002;110:597-603. Go to original source...
    11. Cho WJ, Chow AK, Schulz R, et al. Caveolin-1 exists and may function in cardiomyocytes. Can J Physiol Pharmacol 2010;88:73-76. Go to original source... Go to PubMed...
    12. Pradhan BS, Prószyński TJ. A Role for Caveolin-3 in the Pathogenesis of Muscular Dystrophies. Int J Mol Sci 2020;21:8736. Go to original source... Go to PubMed...
    13. Hardin CD, Vallejo J. Caveolins in vascular smooth muscle: Form organizing function. Cardiovasc Res 2006;69:808-815. Go to original source... Go to PubMed...
    14. Kawabe JI, Grant BS, Yamamoto M, et al. Changes in caveolin subtype protein expression in aging rat organs. Mol Cell Endocrinol 2001;176:91-95. Go to original source... Go to PubMed...
    15. McMurray JJ, Pfeffer MA. Heart failure. Lancet 2005;365:1877-1889. Go to original source... Go to PubMed...
    16. Park DS, Cohen AW, Frank PG, et al. Caveolin-1 null (-/-) mice show dramatic reductions in life span. Biochemistry 2003;42:1512-1531. Go to original source... Go to PubMed...
    17. Patel HH, Murray F, Insel PA. Caveolae as organizers of pharmacologically relevant signal transduction molecules. Annu Rev Pharmacol Toxicol 2008;48:359-391. Go to original source... Go to PubMed...
    18. Nonami A, Taketomi T, Kimura A, et al. The Sprouty-related protein, Spred-1, localizes in a lipid raft/caveola and inhibits ERK activation in collaboration with caveolin-1. Genes Cells 2005;10:887-895. Go to original source... Go to PubMed...
    19. Wunderlich C, Schober K, Lange SA, et al. Disruption of caveolin-1 leads to enhanced nitrosative stress and severe systolic and diastolic heart failure. Biochem Biophys Res Commun 2006;340:702-708. Go to original source... Go to PubMed...
    20. Woodman SE, Park DS, Cohen AW, et al. Caveolin-3 knock-out mice develop a progressive cardiomyopathy and show hyperactivation of the p42/44 mapk cascade. J Biol Chem 2002;277:38988-38997. Go to original source... Go to PubMed...
    21. Hayashi T, Arimura T, Ueda K, et al. Identification and functional analysis of a caveolin-3 mutation associated with familial hypertrophic cardiomyopathy. Biochem Biophys Res Commun 2004;313:178-184. Go to original source... Go to PubMed...
    22. Crossman DJ, Ruygrok PN, Soeller C, et al. Changes in the organization of excitation-contraction coupling structures in failing human heart. PLoS One 2011;6:e17901. Go to original source... Go to PubMed...
    23. Zager RA, Johnson A, Hanson S, et al. Altered cholesterol localization and caveolin expression during the evolution of acute renal failure. Kidney Int 2002;61:1674-1683. Go to original source... Go to PubMed...
    24. Head BP, Patel HH, Tsutsumi YM, et al. Caveolin-1 expression is essential for n-methyl-d-aspartate receptor-mediated src and extracellular signal-regulated kinase 1/2 activation and protection of primary neurons from ischemic cell death. FASEB J 2008;22:828-840. Go to original source... Go to PubMed...
    25. Jasmin JF, Rengo G, Lymperopoulos A, et al. Caveolin-1 deficiency exacerbates cardiac dysfunction and reduces survival in mice with myocardial infarction. Am J Physiol Heart Circ Physiol 2011;300:H1274-H81. Go to original source... Go to PubMed...
    26. Tsutsumi YM, Horikawa YT, Jennings MM, et al. Cardiacspecific overexpression of caveolin-3 induces endogenous cardiac protection by mimicking ischemic preconditioning. Circulation 2008;118:1979-1988. Go to original source... Go to PubMed...
    27. Fridolfsson HN, Patel HH. Caveolin and caveolae in age associated cardiovascular disease. J Geriatr Cardiol 2013;10:66-74. Go to PubMed...
    28. Razani B, Engelman JA, Wang XB, et al. Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities. J Biol Chem 2001;276:38121-38138. Go to original source... Go to PubMed...
    29. Shihata WA, Putra MRA, Chin-Dusting JPF. Is There a Potential Therapeutic Role for Caveolin-1 in Fibrosis? Front Pharmacol 2017;8:567. Go to original source... Go to PubMed...
    30. Zhao YY, Liu Y, Stan RV, et al. Defects in caveolin-1 cause dilated cardiomyopathy and pulmonary hypertension in knockout mice. Proc Natl Acad Sci USA 2002;99:11375-11380. Go to original source... Go to PubMed...
    31. Jasmin JF, Mercier I, Hnasko R, et al. Lung remodeling and pulmonary hypertension after myocardial infarction: Pathogenic role of reduced caveolin expression. Cardiovasc Res 2004;63:747-755. Go to original source... Go to PubMed...
    32. Patel HH, Tsutsumi YM, Head BP, et al. Mechanisms of cardiac protection from ischemia/reperfusion injury: A role for caveolae and caveolin-1. FASEB J 2007;21:1565-1574. Go to original source... Go to PubMed...
    33. Zhu F, Huang J, Wang X, et al. The expression and significance of serum caveolin-1 in patients with Kawasaki disease. Chin J Physiol 2020;63:90-94. Go to original source... Go to PubMed...
    34. Gerbod-Giannone MC, Dallet L, Naudin G, et al. Involvement of caveolin-1 and CD36 in native LDL endocytosis by endothelial cells. Biochim Biophys Acta Gen Subj 2019;1863:830-838. Go to original source... Go to PubMed...
    35. Dou H, Feher A, Davila AC, et al. Role of Adipose Tissue Endothelial ADAM17 in Age-Related Coronary Microvascular Dysfunction. Arterioscler Thromb Vasc Biol 2017;37:1180-1193. Go to original source... Go to PubMed...
    36. Frank PG, Pavlides S, Cheung MW, et al. Role of caveolin-1 in the regulation of lipoprotein metabolism. Am J Physiol Cell Physiol 2008;295:C242-C248. Go to original source... Go to PubMed...
    37. Malinska A, Podemska Z, Sujka-Kordowska P, et al. Caveolin 2: a facultative marker of unfavourable prognosis in long-term patency rate of internal thoracic artery grafts used in coronary artery bypass grafting. Preliminary report. Interact Cardiovasc Thorac Surg 2017;24:714-720. Go to original source... Go to PubMed...
    38. Forrester SJ, Elliott KJ, Kawai T, et al. Caveolin-1 Deletion Prevents Hypertensive Vascular Remodeling Induced by Angiotensin II. Hypertension 2017;69:79-86. Go to original source... Go to PubMed...

    This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0), which permits non-comercial use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content


    Cor et Vasa

    You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

    I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.


    No
    Yes